We’re reading about Trump and patent policies, a new malaria drug
Top of the morning to you, and a fine one it is. Blue skies and comfortable breezes are…
Medicare picks tech firms to run prior authorization pilot
The Centers for Medicare and Medicaid Services has selected the six technology companies that will administer artificial intelligence-powered…
Mark Cuban tries to shake up biosimilar pricing with a version of J&J’s Stelara
In its latest bid to shake up the prescription drug market, the Mark Cuban Cost Plus Drug Company…
New FDA priority review vouchers go to Lilly, Novo, Vertex
WASHINGTON — The Food and Drug Administration on Thursday announced the second batch of companies being granted a “Commissioner’s…
TrumpRx to offer discount weight loss drugs after Lilly, Novo deals
WASHINGTON — The Trump administration announced a deal Thursday to expand access to popular obesity drugs made by…
Pfizer files second lawsuit against Novo Nordisk, Metsera in battle over startup
Pfizer on Monday said it filed a second lawsuit against Novo Nordisk and obesity startup Metsera, alleging that…
SAMHSA cuts endanger people facing addiction or mental illness
O. Rose Broderick reports on the health policies and technologies that govern people with disabilities’ lives. Before coming…
Launch prices for new drugs ‘significantly’ exceed inflation, analysis says
Amid intensifying angst over prescription drug prices, a new analysis found that the median net price for 154…
Kaiser nears Medicare Advantage fraud settlement with DOJ
Tara Bannow covers hospitals, providers, and insurers. You can reach Tara on Signal at tarabannow.70. The Justice Department…
FDA approved fewer drugs in third quarter, analysis finds
The upheaval at the Food and Drug Administration appears to be taking a toll on the pharmaceutical industry,…
Lyra Health launches ‘clinical-grade’ mental health chatbot
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics.…
Sarepta to seek approval for gene therapy in rare muscular dystrophy
An experimental gene therapy from Sarepta Therapeutics increased levels of the gene missing in an ultra-rare form of…